Mr MSc - Idogen AB Chief Officer
| IDOGEN Stock | SEK 0.12 0.00 0.00% |
Insider
Mr MSc is Chief Officer of Idogen AB
| Age | 61 |
| Phone | 46 4 62 75 63 30 |
| Web | https://www.idogen.com |
Idogen AB Management Efficiency
The company has return on total asset (ROA) of (1.3341) % which means that it has lost $1.3341 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (3.2054) %, meaning that it generated substantial loss on money invested by shareholders. Idogen AB's management efficiency ratios could be used to measure how well Idogen AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Louise Aspenberg | Combigene AB | 47 | |
| Karin Agerman | Combigene AB | 50 | |
| Associate Woldbye | Combigene AB | 60 | |
| Stefan MBA | BioInvent International AB | 60 | |
| Ingvar Karlsson | Elicera Therapeutics AB | 67 | |
| Lotta Ferm | Mendus AB | 57 | |
| Cecilia Hofvander | BioInvent International AB | 56 | |
| Matthew Lindon | Lidds AB | 50 | |
| Jenni Bjornulfson | Lidds AB | 52 | |
| RGN MSc | BioInvent International AB | N/A | |
| Anders Mansson | Lidds AB | 56 | |
| Sylvie Ryckebusch | BioInvent International AB | N/A | |
| Leopold Bertea | Mendus AB | 58 | |
| Alex MD | Mendus AB | 73 | |
| Erik Manting | Mendus AB | 52 | |
| PerOlof Gunnesson | Mendus AB | 78 | |
| Pr Essand | Elicera Therapeutics AB | 59 | |
| Jamal MSc | Elicera Therapeutics AB | 42 | |
| Peter Ekolind | Combigene AB | 59 | |
| MD MBA | Mendus AB | 60 | |
| Jan Nilsson | Combigene AB | 74 | |
Management Performance
| Return On Equity | -3.21 | |||
| Return On Asset | -1.33 |
Idogen AB Leadership Team
Elected by the shareholders, the Idogen AB's board of directors comprises two types of representatives: Idogen AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Idogen. The board's role is to monitor Idogen AB's management team and ensure that shareholders' interests are well served. Idogen AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Idogen AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Prof MD, Founder Board | ||
| Hanjing Xie, Chief Officer | ||
| Mr MSc, Chief Officer | ||
| Ingvar Karlsson, Chief Officer | ||
| Rory Graham, Chief Officer | ||
| Christina Herder, Acting Director |
Idogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Idogen AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.21 | |||
| Return On Asset | -1.33 | |||
| Operating Margin | (14.24) % | |||
| Current Valuation | (3.81 M) | |||
| Shares Outstanding | 104.37 M | |||
| Shares Owned By Insiders | 8.35 % | |||
| Shares Owned By Institutions | 0.42 % | |||
| Price To Book | 0.83 X | |||
| Price To Sales | 3.71 X | |||
| Gross Profit | 13.91 M |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Idogen Stock
Idogen AB financial ratios help investors to determine whether Idogen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Idogen with respect to the benefits of owning Idogen AB security.